Synchron
Brain-computer interface developer building minimally-invasive endovascular implants
Biotech
📍 Brooklyn, NY
Founded 2016
Current Valuation
$1.0B
as of 2024-Q4
UNICORN
Synchron's Stentrode is a stent-mounted electrode array implanted via the jugular vein, avoiding open-brain surgery. First BCI company to receive FDA Investigational Device Exemption (IDE) for human trials in the US. Has implanted devices in patients with ALS to enable computer control via thought.
Company Profile
Last Round
Series C — $75M (Dec 2024) · Lead: ARCH Venture Partners
IPO Status
no imminent plans
Founders & Key People
Tom OxleyNicholas OpieRahul Sharma
Investors
ARCH Venture Partners · Khosla Ventures · Bezos Expeditions · Bill Gates · Reliance Industries · NVIDIA
Products
- Stentrode (endovascular BCI)
- BCI.com platform
Competitors
Neuralink · Paradromics · Onward Medical · Blackrock Neurotech
BiotechBCIMedical DeviceBezos Backed
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q4. Refreshed quarterly.